GO
Loading...

Enter multiple symbols separated by commas

Stocks Actavis Inc

More

  • Mylan shareholders approve pursuit of Perrigo Friday, 28 Aug 2015 | 8:12 AM ET

    NEW YORK— Mylan NV's shareholders approved the company's hostile pursuit of Perrigo Co. and the generic drugmaker hopes to push ahead with a formal offer soon. Perrigo, which makes over-the-counter medicines, has resisted repeated overtures from Mylan. In April, Mylan raised its offer for Perrigo to $232.23, or about $34.1 billion, in cash and stock.

  • *Disney, Viacom lead media selloff. Viacom fell 14.22 percent to its lowest in almost four years after reporting lower-than-expected quarterly revenue due to weakness in its cable TV business. The S&P 500 media index lost 2.12 percent and notched its biggest two-day fall since November 2008, with Time Warner, Comcast and CBS all in the red and Twenty-First...

  • Allergan gets DoJ subpoena over generic drug pricing Thursday, 6 Aug 2015 | 4:17 PM ET

    Aug 6- Allergan Plc said on Thursday it received a subpoena from the U.S. Department of Justice seeking information on marketing and pricing of its generic drugs. The subpoena, which the company received in June, also seeks information about communications with competitors regarding the generic products, Allergan said in a regulatory filing.

  • NEW YORK, Aug 6- Generic drugmaker Mylan Inc's chief executive said on Thursday that acquiring Perrigo Co was not a must and that it has other options should Perrigo successfully fend off Mylan's $34 billion hostile offer. However, Mylan CEO Heather Bresch said in an interview that getting the Perrigo deal done remains a top priority and that she still believes...

  • UPDATE 2-Allergan reports better-than-expected revenue Thursday, 6 Aug 2015 | 9:33 AM ET

    Aug 6- Irish drugmaker Allergan Plc reported better-than-expected revenue for the first full quarter since the merger of Actavis and Allergan. Allergan, which changed its name from Actavis after the deal closed, said adding signature drugs like Botox and eye drops Restasis boosted branded products sales five-fold to $3.71 billion in the second quarter...

  • Aug 6- Botox-maker Allergan Plc posted a better-than-expected quarterly adjusted profit as sales of branded drugs rose, helped by acquisition of new products. Allergan did not provide an update to its sales forecast for the full year. Dublin, Ireland- based Allergan's net revenue for the quarter more than doubled to $5.76 billion.

  • Drugmaker Allergan's revenue more than doubles Thursday, 6 Aug 2015 | 7:11 AM ET

    Aug 6- Botox-maker Allergan Plc's quarterly revenue more than doubled, helped by higher sales of its branded drugs in North America. The company reported a net loss attributable to shareholders of $243.1 million, or 80 cents per share, in the second quarter ended June 30, compared with a net profit of $48.7 million, or 28 cents per share, a year earlier.

  • The U.S. Court of Appeals for the Federal Circuit also said five of Allergan's Lumigan patents were valid. The case stems from lawsuits Allergan filed in 2011 against Akorn's Hi-Tech Pharmacal Co Inc, Novartis AG, and Lupin Ltd over proposed generic versions of Lumigan, which has more than $600 million in annual sales. The Allergan patents cover an improved...

  • Paulson, in his first public comments since the recent price crash, said his firm, Paulson& Co. Inc., has retained a 10 million share stake, now worth about $1 billion, in SPDR Gold Trust, which tracks the price of gold. While Paulson's hedge fund was the single largest investor in the SPDR Gold Trust at the end of the first quarter, the position, now worth about $1.05...

  • LONDON, July 31- A surge of takeover activity involving healthcare, financial and retail companies lifted the value of deals in July over $430 billion, making it the seventh-busiest mergers and acquisition month on record, Thomson Reuters data showed. JPMorgan- in second place- advised on 30 deals with a value of $116.1 billion, and third-ranked Morgan Stanley...

  • Teva's MS drug Copaxone has strong second-quarter sales Thursday, 30 Jul 2015 | 8:42 AM ET

    JERUSALEM, July 30- Teva Pharmaceutical Industries, which this week revealed plans to buy Allergan's generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition. Teva, the world's biggest generic drug maker, said that global...

  • Mylan, whose shares fell 14.5 percent, said it would continue its own unsolicited pursuit of Irish drugmaker Perrigo Co, a maker of over-the-counter consumer and nutritional products and generic topical medicines. Perrigo is one of the few remaining assets out there, "said Morningstar analyst Michael Waterhouse. Other industry analysts expect Mylan will...

  • NEW YORK, July 27- Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger. As head of Actavis, he then sealed a $66 billion purchase of Botox-maker Allergan, beating out rival suitor Valeant...

  • *Oil prices, commodities lower following China equity selloff. *Teva, Allergan jump after $40.5 bln deal. U.S.-listed shares of Chinese companies slid, including Alibaba and Baozun.

  • *Oil prices, commodities lower following China equity crash. *Teva, Allergan jump after $40.5 bln deal. The NYSE showed 459 stocks at 52- week lows, the most in a day since Oct. 15.

  • US STOCKS-Wall St slumps after China stocks stumble Monday, 27 Jul 2015 | 12:34 PM ET

    *Teva, Allergan jump after $40.5 bln deal. July 27- Wall Street began the week in the red on Monday and fell sharply on concerns about China's slowing growth in the wake of the biggest drop in Shanghai shares in eight years. China's top securities regulator, China Securities Regulatory Commission, said on Monday that Beijing would continue to buy shares to...

  • NEW YORK, July 27- Allergan CEO Brent Saunders said on Monday the company will use the $36 billion it nets from the sale of its generics business to Teva for more deals, including large, "transformational" merger opportunities. Saunders, who led the $66 billion combination of Actavis and Allergan that closed only a few months ago, told investors that it would use the...

  • US STOCKS-Wall St dips after China stocks tumble Monday, 27 Jul 2015 | 11:19 AM ET

    *Teva, Allergan jump after $40.5 bln deal. July 27- Wall Street began the week in the red on Monday and fell sharply on concerns about China's slowing growth in the wake of the biggest drop in Shanghai shares in eight years. Chinese ADRs including Alibaba, Baozun, Sohu.com and JD.com slid.

  • *Teva, Allergan jump after $40.5 bln deal. July 27- Wall Street began the week in the red on Monday and fell sharply on concerns about China's slowing growth in the wake of the biggest drop in Shanghai shares in eight years. Chinese ADRs including Alibaba, Baozun, Sohu.com and JD.com slid.

  • TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a cash and stock deal that will turn the Israeli company into one of the world's largest pharmaceutical firms. It also will allow Dublin- based Allergan, the third-largest generic drugmaker in the United States, to focus on branded drugs...